A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma

Cancer Chemotherapy and Pharmacology
Christopher W RyanEverett E Vokes

Abstract

Tumor resistance to alkylating agents such as carmustine (BCNU) has been found to be associated with intracellular expression of O6-methylguanine-DNA methyltransferase (MGMT). Administration of O6-benzylguanine (O6-BG), a substrate that inactivates MGMT, may help overcome chemotherapy resistance. We performed a phase II study to explore the activity of O6-BG in combination with BCNU in patients with advanced soft tissue sarcoma. Informed consent was obtained from patients with metastatic soft tissue sarcoma naïve to systemic chemotherapy (adjuvant chemotherapy allowed). Patients received O6-BG 120 mg/m2 I.V. followed by BCNU 40 mg/m2 I.V. Treatment was repeated every 6 weeks until disease progression or development of unacceptable toxicity. No objective responses were observed in 12 enrolled patients. Four patients exhibited stable disease lasting 11-25+ weeks. The median overall survival was 16.9 months (95% CI, 2.9-NR). The most common grade 3-4 toxicities were neutropenia, thrombocytopenia, and anemia. Depletion of MGMT activity was demonstrated in peripheral blood mononuclear cells. Immunohistochemical estimation of MGMT expression from archival tissue ranged from 20 to 99% positive staining cells. Observed toxicities were ...Continue Reading

References

May 1, 1992·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·J M BullA S Tonnesen
Apr 1, 1992·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J VerweijJ Buesa
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D J WagenerM van Glabbeke
Mar 1, 1987·European Journal of Cancer & Clinical Oncology·V H BramwellR Sylvester
Jan 1, 1995·Progress in Nucleic Acid Research and Molecular Biology·A E PeggR C Moschel
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K AntmanD L Trump
May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M E DolanM J Ratain
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S FriedmanS C Schold
Dec 16, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S FriedmanP L Modrich
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S FriedmanM E Dolan
Nov 9, 2000·The New England Journal of Medicine·M EstellerJ G Herman
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer A QuinnHenry S Friedman
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp

❮ Previous
Next ❯

Citations

Sep 8, 2010·Cancer Metastasis Reviews·Athanasios G Pallis, Michalis V Karamouzis
Dec 25, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N PenelP Hohenberger
Nov 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H A TawbiJ M Kirkwood
Dec 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ruth PlummerHilary Calvert
Feb 9, 2008·Pharmacology·Howard R Mellor, Richard Callaghan
Aug 19, 2010·Cellular and Molecular Life Sciences : CMLS·Bernd KainaMarkus Christmann
Oct 10, 2007·Expert Opinion on Investigational Drugs·Omar Khan, Mark R Middleton
May 16, 2006·Cancer Treatment Reviews·Cara A RabikM Eileen Dolan
Apr 9, 2015·BMC Cancer·Sangeetha Sukumari-RameshKrishnan M Dhandapani
Jul 29, 2009·Cancer Treatment Reviews·Yongjian ZhuWeiguo Liu
Jun 15, 2011·Cancer Control : Journal of the Moffitt Cancer Center·Damon Reed, Soner Altiok
Jun 13, 2015·Cancer Control : Journal of the Moffitt Cancer Center·Jenny M Kreahling, Soner Altiok
Jul 14, 2018·Future Medicinal Chemistry·Guohui SunYongzhen Peng
Oct 30, 2007·Neurologic Clinics·Robert CavaliereDavid Schiff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Thomas F GajewskiEverett E Vokes
Cancer Chemotherapy and Pharmacology
Eric D BattsStanton L Gerson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jennifer A QuinnHenry S Friedman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jennifer A QuinnHenry S Friedman
© 2021 Meta ULC. All rights reserved